Drawing for PROGRESS IN MIND

USPTO serial 86327265

PROGRESS IN MIND

Reviewed by CopyMark Law Group

Reg. 4763308Status 800Registered
Filing date
Status date
Registration date
Jun 30, 2015
Examiner
PAQUIN, SAMUEL ROBERT
Law office
PUBLICATION AND ISSUE SECTION

What this means

Status 800 means the registration was renewed after acceptable combined Section 8 and Section 9 filings. The mark remains registered for another 10-year term with active federal protection. Calendar the next Section 8 and 9 deadline in 10 years and maintain monitoring.

Status 800: Status 800 means the registration was renewed after acceptable combined Section 8 and Section 9 filings. The mark remains registered for another 10-year term with active federal protection.

Need help with PROGRESS IN MIND?

If you own this trademark, we can monitor new filings and help with USPTO deadlines. If you do not, we can file a new U.S. application.

Current trademark owner
Monitor this mark, or talk with CopyMark about this registration.
Not the owner?
File a new U.S. trademark application, or speak with our attorneys.

Owner

Attorney of record

The USPTO lists this attorney as the applicant's representative for correspondence on this application.

Maren C. Perry

Maren C. Perry King & Spalding LLP1185 Avenue of the AmericasNew York, NY 10036United States

Goods and services

ClassDescriptionStatusFirst use
005[ Pharmaceutical preparations for the treatment and prevention of brain and central nervous system diseases and disorders; vaccines; pharmaceutical preparations and substances for the prevention and treatment of disorders and diseases in, generated from or acting on the brain and central nervous system; pharmaceutical preparations and substances for the prevention and treatment of disorders and diseases in, generated from or acting on the brain and central nervous system; pharmaceutical preparations and substances acting on the brain and central nervous system; central nervous system stimulants; pharmaceutical preparations and substances for the prevention and treatment of brain and central nervous system diseases and disorders; pharmaceutical preparations and substances for the prevention and treatment of Alzheimer's disease and disorder, depression, mood disorder, psychosis, stroke, anxiety, epilepsy, multiple sclerosis, porphyria, Huntington's disease and disorder, insomnia, Parkinson's disease and disorder, schizophrenia, bipolar disorder and disease, oncology, pain, alcoholism, alcohol dependence and addiction; medical diagnostic preparations, substances, reagents and agents ]SECTION 8 - CANCELLED—
009[ Downloadable electronic publications, namely, books, reports, brochures, booklets, leaflets, patient information leaflets, magazines, journals, teaching and educational material all in the field of medical and pharmaceutical research and development, science, clinical tests and trials, medical diagnostics, medicine, pharmaceuticals, disorders, diseases, treatment and prevention of brain and central nervous system diseases and disorders; recorded computer software, namely, database management software for medical and pharmaceutical information, education activities; computer operating software for websites, intranet, and internet; data processing equipment and computers; application software for mobile devices and software applications all for managing patient medical information and interaction ]SECTION 8 - CANCELLED—
041Arranging and conducting educational seminars, conferences, symposiums, workshops, training, and courses in the field of medicine; educational classes, courses, seminars, and workshops and training services in the field of medical research and development, science, clinical tests and trials, diagnostic, medicine, pharmaceuticals, disorders, diseases, treatment and prevention of disease; educational classes, courses, seminars, and workshops and training services in the field of medical research and development, science, clinical tests and trials, diagnostic, medicine, pharmaceuticals, disorders, diseases, treatment and prevention of disease provided electronically, on-line, via the internet, and global communications networks; education services, namely, arranging and conducting of expert forums in the form of seminars, conferences, symposia, workshops and courses in the field of medicine; on-line medical training programs; providing non-downloadable on-line publications, namely, books, reports, brochures, booklets, leaflets, patient information leaflets, magazines, journals, teaching and educational material in the field of medical research and development, science, clinical tests and trials, medical diagnostics, medicine, pharmaceuticals, disorders, diseases, treatment and prevention of disease ]SECTION 8 - CANCELLED—
042[ Scientific and technological services, namely, research and design in the field of medicine; industrial analysis and research services in the field of pharmaceuticals; providing online non-downloadable software and an online searchable database in the field of research and development, science, clinical tests and trials, diagnostic, medicine, pharmaceuticals, disorders, diseases, treatment and prevention for the purpose of scientific research; providing a secured access website that gives medical experts the ability to upload, view, download, and share documents and images for the purposes of research and development in the field of clinical tests and trials, science, patient diagnostics, medicine, pharmaceuticals, disorders, diseases, treatment and prevention of disease; pharmaceutical research and development; scientific and technological services, namely, research in the field of medical disorders, diseases, and prevention of disease; scientific and technological services, namely, research regarding the prevention and treatment of brain and central nervous system diseases and disorders; medical research, conducting medical trials for others and testing of pharmaceuticals; conducting clinical research, trials, and testing in the field of pharmaceuticals for others; medical diagnostic research and tests, including clinical trials for others; providing for medical information in the field of pharmaceutical research and development, science, clinical tests and trials ]SECTION 8 - CANCELLED—
044[ Medical services in the field of the treatment and prevention of brain and central nervous system diseases and disorders; medical advice in the field of medical and pharmaceutical preparations and substances; medical treatment services in the field of brain and central nervous systems diseases and disorders; therapeutic treatment services in the field of brain and central nervous system diseases and disorders; therapeutic clinical services in the field of brain and central nervous system diseases and disorders; healthcare and medical services related to central nervous system and brain disorders, diseases and pharmaceuticals; ] providing medical and medicinal information in the field of diagnostic, medicine, pharmaceuticals, disorders, diseases, treatment and prevention; medical information services [ ; providing on-line medical data and analyses designed to provide patients and clients customized information, including medical dose, diagnosis, therapeutic issues and medical management ]ACTIVE—

Related trademarks

CopyMark links this record to cited §2(d) serials, the owner's other marks, Nice classes, similar mark names, and recently changed USPTO applications.

Prosecution history

DateCodeEventWhat it means
Oct 9, 2025NA89NOTICE OF ACCEPTANCE OF SEC. 8 & 9 - E-MAILED—
Oct 9, 2025RNL1REGISTERED AND RENEWED (FIRST RENEWAL - 10 YRS)The trademark registration was renewed for another 10-year term after acceptable maintenance filings. RNL1, RNL2, and RNL3 indicate which renewal cycle (first, second, or third 10-year term) was recorded. The registration remains active.
Oct 9, 202589AGREGISTERED - SEC. 8 (10-YR) ACCEPTED/SEC. 9 GRANTEDThe USPTO accepted your combined Section 8 declaration and Section 9 renewal application. The registration is renewed for another 10-year term. The next combined maintenance filing will be due at the following 10-year anniversary.
Oct 9, 2025APRECASE ASSIGNED TO POST REGISTRATION PARALEGAL—
Jun 17, 2025E89RTEAS SECTION 8 & 9 RECEIVED—
Jun 30, 2024REM2COURTESY REMINDER - SEC. 8 (10-YR)/SEC. 9 E-MAILED—
Mar 22, 2024TCCATEAS CHANGE OF CORRESPONDENCE RECEIVED—
Mar 22, 2024ECDRTEAS CHANGE OF DOMESTIC REPRESENTATIVES ADDRESS—
Mar 22, 2024EWORTEAS WITHDRAWAL AS DOMESTIC REPRESENTATIVE RECEIVED—
Mar 22, 2024ARAAATTORNEY/DOM.REP.REVOKED AND/OR APPOINTEDThis event means the applicant filed a response to a USPTO Office Action — typically arguments, amendments, or evidence addressing the examiner's objections. The USPTO will review the response and either allow the mark to proceed or issue another action.
Mar 22, 2024REAPTEAS REVOKE/APP/CHANGE ADDR OF ATTY/DOM REP RECEIVED—
Dec 1, 2022NAS8NOTICE OF ACCEPTANCE OF SEC. 8 - E-MAILED—
Dec 1, 20228.PRREGISTERED - PARTIAL SEC. 8 (6-YR) ACCEPTED—
Nov 30, 2022EROPTEAS RESPONSE TO OFFICE ACTION-POST REG RECEIVED—
Jun 2, 2022PRA8POST REGISTRATION ACTION MAILED - SEC. 8—
Jun 2, 2022APRECASE ASSIGNED TO POST REGISTRATION PARALEGAL—
Dec 29, 2021ES8RTEAS SECTION 8 RECEIVED—
Jun 30, 2020REM1COURTESY REMINDER - SEC. 8 (6-YR) E-MAILED—
Jun 30, 2015R.PRREGISTERED-PRINCIPAL REGISTERYour trademark is registered on the Principal Register — the strongest form of federal trademark protection. You may use the ® symbol for the covered goods and services. Maintenance filings (Section 8 and renewals) are required to keep the registration alive.
Apr 14, 2015NPUBOFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED—
Apr 14, 2015PUBOPUBLISHED FOR OPPOSITIONYour mark was published in the USPTO Official Gazette for a 30-day opposition window. During that period, third parties who believe they would be harmed can file an opposition. If no opposition is filed, prosecution usually continues toward registration or a Notice of Allowance.
Mar 25, 2015NONPNOTIFICATION OF NOTICE OF PUBLICATION E-MAILED—
Mar 6, 2015PREVLAW OFFICE PUBLICATION REVIEW COMPLETED—
Mar 5, 2015CNSAAPPROVED FOR PUB - PRINCIPAL REGISTER—
Mar 4, 2015TEMETEAS/EMAIL CORRESPONDENCE ENTERED—
Mar 4, 2015CRFACORRESPONDENCE RECEIVED IN LAW OFFICE—
Feb 25, 2015ALIEASSIGNED TO LIE—
Feb 18, 2015TROATEAS RESPONSE TO OFFICE ACTION RECEIVEDThis event means the applicant filed a response to a USPTO Office Action — typically arguments, amendments, or evidence addressing the examiner's objections. The USPTO will review the response and either allow the mark to proceed or issue another action.
Sep 25, 2014GNRNNOTIFICATION OF NON-FINAL ACTION E-MAILEDA non-final Office Action means the USPTO examining attorney has raised at least one issue with your trademark application but has not made a final decision. You usually have three months to respond with arguments, amendments, or evidence. Missing the deadline can abandon the application.
Sep 25, 2014GNRTNON-FINAL ACTION E-MAILEDA non-final Office Action means the USPTO examining attorney has raised at least one issue with your trademark application but has not made a final decision. You usually have three months to respond with arguments, amendments, or evidence. Missing the deadline can abandon the application.
Sep 25, 2014CNRTNON-FINAL ACTION WRITTENA non-final Office Action means the USPTO examining attorney has raised at least one issue with your trademark application but has not made a final decision. You usually have three months to respond with arguments, amendments, or evidence. Missing the deadline can abandon the application.
Sep 19, 2014DOCKASSIGNED TO EXAMINER—
Jul 9, 2014NWOSNEW APPLICATION OFFICE SUPPLIED DATA ENTERED—
Jul 5, 2014NWAPNEW APPLICATION ENTERED—

Frequently asked questions

Related guidance